Anti-Candida Drugs — The Biochemical Basis for Their Activity

References

• Medoff G., Kobayashi G. A. The polyenes. Antifungal Chemotherapy, D. C. E. Speller. John Wiley & Sons, London 1980; 3
   Google Scholar
• Ryley J., Wilson R. G., Gravestock M. B., Payser J. P. Experimental approaches to antifungal chemotherapy, Adv. Pharmacol. Chemother. 1981; 18: 49
   PubMedGoogle Scholar
• Hamilton-Miller J. M. T. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol. Rev. 1973; 37: 166
   Google Scholar
• Mechlinski W., Schaffner C. P., Ganis P., Avitabile G. Structure and absolute configuration of the polyene antibiotic amphotericin B. Tetrahedron Lett. 1970; 44: 3873
   Google Scholar
• Ganis P., Avitabile G., Mechlinski W., Schaffner C. P. Polyene macrolide antibiotic amphotericin B. Crystal structure of the N-iodoacetyl derivative. J. Am. Chem. Soc. 1971; 93: 4560
   PubMed Web of Science ®Google Scholar
• Andreoli T. E. The structure and function of amphotericin B-cholesterol pores in lipid bilayer membranes. Ann. N.Y. Acad. Sci. 1974; 235: 448
   PubMed Web of Science ®Google Scholar
• Storch J., Kleinfeld A. M. The lipid structure of biological membranes. TIBS November, 1985; 418
   Google Scholar
• Bergan T., Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy 1983; 29: 104
   Google Scholar
• Sugar A. M. The polyene macrolide antifungal drugs. The Antimicrobial Agents Annual, P. K. Peterson, J. Verhoef. Elsevier, Amsterdam 1986; Vol. 1: 229
   Google Scholar
• Sande M. A., Mandell G. L. Antimicrobial agents. Antifungal and antiviral agents. Goodman and Gilman's The Pharmaceutical Basis of Therapeutics7th ed., A. Goodman-Gilman, L. S. Goodman, T. W. Rall, F. Murad. MacMillan, New York 1985; 1219
   Google Scholar
• Graybill J. R., Craven P. C. Antifungal agents used in systemic mycosis: activity and therapeutic use. Drugs 1983; 25: 41
   PubMed Web of Science ®Google Scholar
• Kennedy M. S., Deeg H. J., Siegel M., Crowley J. J., Storb R., Thomas E. D. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983; 35: 211
   PubMed Web of Science ®Google Scholar
• Medoff G., Brajtburg J., Kobayashi G. S. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 1983; 23: 303
   PubMed Web of Science ®Google Scholar
• Palacios J., Serrano R. Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast. FEBS Lett. 1978; 91: 198
   Google Scholar
• Heredia C. F., Sols A., Fuente Dela G. Specificity of the constitutive hexose transport in yeast. Eur. J. Biochem. 1968; 5: 321
   Google Scholar
• Serrano R. Energy requirements for maltose transport in yeast. Eur. J. Biochem. 1977; 80: 97
   PubMedGoogle Scholar
• Pena A. Studies on the mechanism of K+ transport in yeast. Arch. Biochem. Biophys. 1975; 167: 397
   Google Scholar
• Lampen J. O. Amphotericin B and other polyenic antifungal antibiotics. Am. J. Clin. Pathol. 1969; 52: 138
   Google Scholar
• Goffeau A., Slayman C. W. The proton-translocating ATPase of the fungal plasma membrane. Biochim. Biophys. Acta 1981; 639: 197
   PubMed Web of Science ®Google Scholar
• Gale E. F., Cundliffe E., Reynolds P. E., Richmond M. H., Waring M. J. The Molecular Basis of Antibiotic Action. John Wiley & Sons, London 1982; 201
   Google Scholar
• Kerridge D., Whelan W. L. The polyene macrolide antibiotics and 5-fluorocytosine: molecular actions and interactions. Mode of Action of Antifungal Agents, A. P. J. Trinci, J. F. Ryley. Cambridge University Press, Cambridge 1984; 343
   Google Scholar
• Gale E. F. The release of potassium ions from Candida albicans in the presence of polyene antibiotics. J. Gen. Microb. 1974; 87: 20
   Google Scholar
• Readio J. D., Bittman R. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. Biochim. Biophys. Acta 1982; 685: 219
   PubMed Web of Science ®Google Scholar
• Teerlink T., De Kruyff B., Demel R. A. The action of pimaricin, etrescomycin and amphotericin B on liposomes with varying sterol content. Biochim. Biophys. Acta 1980; 599: 484
   Google Scholar
• De Kruyff B., Gerritsen V. J., Oerlemans A., Van Dyck P. W. M., Demel R. A., Van Deenen L. L. M. Polyene antibiotic sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. II. Temperature dependence of the polyene antibiotic-sterol complex formation. Biochim. Biophys. Acta 1974; 339: 44
   Google Scholar
• Kim S. J., Kwon-Chung K. J., Milne G. W. A., Prescott B. Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols. Antimicrob. Agents Chemother. 1974; 6: 405
   PubMedGoogle Scholar
• Fryberg M., Oehlschlager A. C., Unrau A. M. Sterol biosynthesis in antibiotic-resistant yeast: nystatin. Arch. Biochem. Biophys. 1974; 160: 83
   Google Scholar
• Scholer H. J. Flucytosine. Antifungal Chemotherapy, D. C. E. Speller. John Wiley & Sons, New York 1980; 35
   Google Scholar
• Hamilton-Miller J. M. T. A comparative in vitro study of amphotericin B, clotrimazole and 5-fluorocytosine against clinically isolated yeasts. Sabouraudia 1972; 10: 276
   PubMedGoogle Scholar
• Ellis D., Jarvinen A., Hansman D. Effect of pH on in vitro antifungal drug sensitivity testing. Recent Advances in Chemotherapy, Antimicrobial Section, J. Ishigami. University of Tokyo Press, Tokyo 1985; Vol. 3: 2554
   Google Scholar
• Polak A., Grenson M. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans. Eur. J. Biochem. 1973; 32: 276
   PubMedGoogle Scholar
• Forêt M., Schmidt R., Reichert U. On the mechanism of substrate binding to the purine-transport system of Saccharomyces cerevisiae. Eur. J. Biochem. 1978; 82: 33
   Google Scholar
• Polak A. Mode of action of 5-fluorocytosine. Rev. Inst. Pasteur Lyon 1980; 13: 233
   Google Scholar
• Waldorf A. R., Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob. Agents Chemother. 1983; 23: 79
   PubMed Web of Science ®Google Scholar
• Danenberg P. V. Thymidilate synthetase — a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 1977; 473: 73
   PubMed Web of Science ®Google Scholar
• Medoff G., Comfort M., Kobayashi G. S. Synergystic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc. Soc. Exp. Biol. Med. 1971; 138: 571
   PubMed Web of Science ®Google Scholar
• Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc. Natl. Acad. Sci. U.S.A. 1972; 69: 196
   PubMed Web of Science ®Google Scholar
• Ryder N. S. Biochemical mode of action of the allylamine antimycotic agents naftiftne and SF-86–327. In Vitro and in Vivo Evaluation of Antifungal Agents, K. Iwata, H. Vanden Bossche. Elsevier, Amsterdam 1986; 89
   Google Scholar
• Anon. Naftifine. Drugs Fut. 1980; 5(3)141
   Google Scholar
• Petranyi G., Ryder N. S., Stütz A. Allylamine derivative: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239
   PubMed Web of Science ®Google Scholar
• Petranyi G., Meingassner J. G., Mieth H. SF86–327: a new antimycotic agent and its activity in laboratory animals. Poster session, 13th ICC. Vienna 1983, PS 4.8/4–5
   Google Scholar
• Ryder N. S. Specific inhibition of fungal sterol biosynthesis by SF 86–327, a new allylamine antimycotic agent. Antimicrob. Agents Chemother. 1985; 27: 252
   PubMed Web of Science ®Google Scholar
• Ryder N. S., Frank I., Dupont M.-C. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob. Agents Chemother. 1986; 29: 858
   PubMed Web of Science ®Google Scholar
• Paltauf F., Daum G., Zuder G., Högenauer G., Schulz G., Seidl G. Squalene and ergosterol biosynthesis in fungi treated with naftifine, a new antimycotic agent. Biochim. Biophys. Acta 1982; 712: 268
   Google Scholar
• Barrett-Bee K. J., Lane A. C., Turner R. W. The mode of antifungal action of tolnaftate. J. Med. Vet. Mycol. 1986; 24: 155
   PubMedGoogle Scholar
• Odds F. C. Laboratory tests for the activity of imidazole and triazole antifungal agents in vitro. Semin. Dermatol. 1985; 4: 260
   Google Scholar
• Van Cutsem J., Van Gerven F., Janssen P. A. J. The in vitro evaluation of azoles. In Vitro and in Vivo Evaluation of Antifungal Agents, K. Iwata, H. Vanden Bossche. Elsevier, Amsterdam 1986; 51
   Google Scholar
• Espinel-Ingroff A., Shadomy S., Gelhart R. J. In vitro studies with R 51 211 (Itraconazole). Antimicrob, Agents Chemother. 1984; 26: 5
   PubMed Web of Science ®Google Scholar
• Shadomy S., Espinel-Ingroff A., Gelhart R. J. In vitro studies with SF86–327, a new orally active allyiamine derivative. Sabouraudia 1985; 23: 125
   PubMedGoogle Scholar
• Van Cutsem J., Van Gerven F., Janssen P. A. J. Intraconazole, orally, topically and parenterally active in superficial and deep mycoses. Rev. Infect. Dis. 1987; 9: 515
   Google Scholar
• Symoens J., Cauwenbergh G. Ketoconazole, a new step in the management of fungal disease. Progress in Drug Research, E. Jucker. Birkhäuser Verlag, Basel 1983; Vol. 27: 63
   Google Scholar
• Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16: 201
   Google Scholar
• Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses activity and therapeutic use. Drugs 1983; 25: 41
   PubMed Web of Science ®Google Scholar
• Rippon J. W. A new era in antimycotic agents. Arch. Dermatol. 1986; 122: 399
   PubMedGoogle Scholar
• Intraconazole. Basic Medical Information Brochure5th Ed. Janssen Pharmaceutica, Clinical Department, BeerseBelgium May, 1986, R 51 211
   Google Scholar
• Van Cutsem J., Janssen P. A. J. Antifungal activity of new azoles. Recent Advances in Chemotherapy, Antimicrobial Section, J. Ishigami. University of Tokyo Press, Tokyo 1986; Vol. 3: 1942
   Google Scholar
• Marichal P., Gorrens J., Vanden Bossche H. The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger. Sabouraudia J. Med. Vet. Mycol. 1985; 23: 13
   Google Scholar
• Lavrijsen K., Van Houdt J., Thijs D., Meuldermans W., Heykants J. Induction potential of antifungals containing an imidazole or triazole moiety. Biochem. Pharmacol. 1986; 35: 1867
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H., Bellens D., Cools W., Gorrens J., Marichal P., Verhoeven H., Willemsens G., De Coster R., Beerens D., Haelterman C., Coene M.-C., Lauwers W., Le Jeune L. Cytochrome P-450: target for itraconzole. Drug Dev. Res. 1986; 8: 287
   Google Scholar
• Vanden Bossche H., De Coster R., Amery W. K. Pharmacology and Clinical Uses of Inhibition of Hormone Secretion and Action, B. Furr, A. E. Wakeling. Baillière Tindall, London 1987; 288
   Google Scholar
• Levine H. B. Ketoconazole in The Management of Fungal Disease. ADIS Press, New York 1982
   Google Scholar
• Vanden Bossche H., Lauwers W., Willemsens G., Cools W. The cytochrome P-450 dependent C17,20-lyase in subcellular fraction of rat testis: differences in sensitivity to ketoconazole and itraconazole. Microsomes and Drug Oxidations, A. R. Boobis, J. Caldwell, F. de Matteis, C. R. Elcombe. Taylor and Francis, London 1985; 187
   Google Scholar
• Amery W. K., De Coster R., Caers L. I. Ketoconazole: from an antimycotic to a prostate-cancer drug. Drug Dev. Res. 1986; 8: 299
   Google Scholar
• Richardson K., Andrews R. J., Marriott M. S., Tarbit M. H., Troke P. F. Correlation of in vitro and in vivo activity of azole antifunals. In Vitro and in Vivo Evaluation of Antifungal Agents, K. Iwata, H. Vanden Bossche. Elsevier, Amsterdam 1986; 147
   Google Scholar
• Jevons S., Lees L., Tarbit M. Early clinical experience with UK-49–858 in human volunteers and patients. Recent Advances in Chemotherapy, Antimicrobial Section, J. Ishigami. University of Tokyo Press, Tokyo 1938; Vol. 3, 1986
   Google Scholar
• Marriott M. S., Humphrey M. J., Tarbit M. H. UK-49,858: a new triazole antifungal drug with novel pharmacokinetic properties in laboratory animals. Recent Advances in Chemotherapy, Antimicrobial Section, J. Ishigami. University of Tokyo Press, Tokyo 1934; Vol. 3, 1986
   Google Scholar
• Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49858, a metabolically stable triazole antifungal drug in animals and humans. Antimicrob. Agents Chemother. 1985; 28: 648
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Current Topics in Medical Mycology, M. R. McGinnis. Springer Verlag, New York 1985; Vol. 1: 313
   Google Scholar
• Sisler H. O., Ragsdale N. N. Biochemical and cellular aspects of the antifungal action of ergosterol biosynthesis inhibitors. Mode of Action of Antifungal Agents, A. P. J. Trinci, J. F. Ryley. Cambridge University Press, Cambridge 1984; 257
   Google Scholar
• Gadher P., Mercer E. I., Baldwin B. C., Wiggins T. E. A comparison of the potency of some fungicides as inhibitors of sterol 14-demethylation. Pestic. Biochem. Physiol. 1983; 19: 1
   Google Scholar
• Henry M. J. Effect of Sterol Biosynthesis Inhibiting (SBI) Fungicides on Cytochrome P-450 Oxygenations. Ph.D. thesis, University of Maryland, College Park 1982
   Google Scholar
• Yoshida Y., Aoyama Y. Interaction of azole derivatives with yeast cytochrome P-450 which catalyzes lanosterol 14α-demethylation. In Vitro and in Vivo Evaluation of Antifungal Agents, K. Iwata, H. Vanden Bossche. Elsevier, Amsterdam 1986; 123
   Google Scholar
• Vanden Bossche H., Willemsens G., Marichal P., Cools W., Lauwers W. The molecular basis for the antifungal activites of N-substituted azole derivatives. Focus on R 51 211. Mode of Action of Antifungal Agents, A. P. J. Trinci, J. F. Ryley. Cambridge University Press, Cambridge 1984; 321
   Google Scholar
• Vanden Bossche H., Bellens D., Gorrens J., Marichal P., Verhoeven H., Willemsens G. yeast and plant cytochrome P-450 enzymes: targets for azole derivatives. Cytochrome P-450 Biochemistry, Biophysics and Induction, L. Vereczkey, K. Magyar. Akadémiai Kiado, Budapest 1985; 423
   Google Scholar
• Chiew Y. Y., Sullivan P. A., Shepherd M. G. The effects of ergosterol and alcohols on germ-tube formation and chitin synthase in Candida albicans. Can. J. Biochem. 1982; 60: 15
   PubMedGoogle Scholar
• Roberts R. L., Bowers B., Slater M. L., Cabib E. Chitin synthesis and localization in cell division cycle mutants of Saccharomyces cerevisiae. Mol. Cell. Biol. 1983; 3: 922
   PubMed Web of Science ®Google Scholar
• Horsburgh C. R., Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am. J. Med. 1983; 74(Suppl. IB)23
   Google Scholar
• Johnson E. M., Richardson M. D., Warnock D. W. In vitro resistance to imidazole antifungals in Candida albicans. J. Antimicrob. Chemother. 1984; 13: 547
   PubMed Web of Science ®Google Scholar
• Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia J. Med. Vet. Mycol. 1984; 22: 53
   Google Scholar
• Smith K. J., Warnock D. W., Kennedy C. T. C., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J. Med. Vet. Mycol. 1986; 24: 133
   PubMedGoogle Scholar
• Vanden Bossche H., unpublished results
   Google Scholar